Diplomat Pharmacy, Inc. (NYSE: DPLO)
According to the Complaint, Diplomat Pharmacy, Inc, through its specialty pharmacy and infusion services, helps people with complex and chronic health conditions in all fifty states and Washington, D.C., partnering with
payers, providers, hospitals, and manufacturers.
This action stems from a proposed transaction announced on December 9, 2019, pursuant to which Diplomat Pharmacy, Inc. will be acquired by affiliates of OptumRx, Inc.
On December 9, 2019, Diplomat’s Board of Directors caused the Company to enter into an agreement and plan of merger with UnitedHealth Group Incorporated.
On January 9, 2020, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.